Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating reaffirmed by analysts at Numis Securities Ltd in a research note issued on Tuesday. They presently have a GBX 275 ($3.71) price objective on the stock. Numis Securities Ltd’s price objective would suggest a potential upside of 54.49% from the stock’s current price.

Shares of Ergomed PLC (LON ERGO) traded up 4.71% on Tuesday, reaching GBX 178.00. 17,850 shares of the company were exchanged. The stock’s 50-day moving average is GBX 181.87 and its 200 day moving average is GBX 194.27. Ergomed PLC has a 12-month low of GBX 118.00 and a 12-month high of GBX 216.88. The firm’s market capitalization is GBX 72.27 million.

Ergomed PLC (LON:ERGO) last issued its earnings results on Monday, September 18th. The company reported GBX 1.20 ($0.02) earnings per share (EPS) for the quarter. The business had revenue of GBX 2,291 million during the quarter. Ergomed PLC had a negative return on equity of 0.92% and a negative net margin of 0.72%. On average, analysts forecast that Ergomed PLC will post $7.80 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at

About Ergomed PLC

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services.

Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with's FREE daily email newsletter.